Clinical Trial Update: Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reporting ongoing phase 2 and phase 3 studies evaluating the combination of anlotinib with immune checkpoint inhibitors for non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING